Sana Biotechnology is advancing its IND application with GMP Master Cell Bank development and trials conducted at Uppsala University Hospital.
1 report, 1 independent
Updated Aug 4
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Sana Biotechnology is advancing its IND application with GMP Master Cell Bank development and trials conducted at Uppsala University Hospital.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Per-Ola Carlsson is appointed as the study principal investigator for Sana Biotechnology's ongoing treatments.Sub-event
- Sana Biotechnology delivered encouraging six-month data on its allogeneic CAR-T platform for Type 1 diabetes.Sub-event
Sana is moving forward with GMP Master Cell Bank and conducting trials for its IND application.1 source
Keep exploring
The entities involved
-
Sana Biotechnology
biotechnology company
Nothing else this week.
- FDA
Related events
- A network focused on cell and gene therapies is expanding to include sites in Northern California, involving the CA Institute for Regenerative Medicine and the FDA.
- Fate Therapeutics, based in San Diego, is seeking support for an accelerated regulatory pathway from the FDA.
- Capricor Therapeutics is seeking regulatory approval from the FDA for clinical trials and has listed on the Nasdaq stock exchange, with a law firm based in New York City involved.
- FDA approval enables commercial opportunity involving CBRE Group.
- Decoy Therapeutics is listed on the Nasdaq stock exchange and is currently seeking expedited regulatory approval via FDA pathways.
Coverage
Newest first; wire copies grouped- GlobeNewswireSana Biotechnology Announces Publication in New England Journal of Medicine of Groundbreaking Clinical Data from Transplantation Without Immunosuppression of Hypoimmune-Modified, Insulin-Producing Isl